2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of …
… In REWIND, the dulaglutide point estimate for MACE in primary prevention was identical to that for secondary prevention (HR: 0.87; 95% CI: 0.74 to 1.02 for both), and dulaglutide is …..... Read More